- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07561359
12-Week Strength and Functional Exercise Program for Hereditary Spastic Paraplegia Trial (HSPMOVE) (HSPMOVE)
12-Week Strength and Functional Exercise Protocol for Treating Motor Symptoms in Individuals With Hereditary Spastic Paraplegia: Adaptive Randomized Crossover Clinical Trial
This study aims to evaluate whether a 12-week program of strength and functional exercises can improve movement and daily function in people with Hereditary Spastic Paraplegia (HSP). Participants will take part in supervised exercise sessions twice a week, delivered by videoconference, with guidance from a physiotherapist. The exercises will be tailored to each participant's abilities and goals and will focus on improving muscle strength, balance, and walking.
The study is a randomized crossover trial, meaning that all participants will experience both the exercise program and a comparison period without the intervention.
Eligible participants are individuals aged 16 to 70 years with a clinical or genetically confirmed diagnosis of HSP, who are able to walk independently (with or without assistive devices) and have stable treatment for spasticity.
Researchers will measure changes in walking ability, balance, muscle strength, and quality of life using clinical scales and functional tests. These include walking tests, mobility assessments, and questionnaires about daily activities and confidence in movement. To reduce bias, outcome assessments will be performed by an evaluator who is blinded to the participants' group allocation.
The results of this study will help determine whether a structured exercise program is safe, feasible, and effective for improving motor symptoms in people with HSP, and may support its use as part of routine care.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
Rio Grande do Sul
-
Porto Alegre, Rio Grande do Sul, Brasil, 90035-003
- Centro de Pesquisa Clínica do Hospital de Clínicas de Porto Alegre
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Filho
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Descrição
Inclusion Criteria:
- Diagnosis of hereditary spastic paraplegia confirmed by genetic testing or clinical diagnosis with a positive family history
- Age between 16 and 70 years
- Independent ambulation, with or without assistive devices
- Access to an electronic device (smartphone, tablet, or computer) with camera and internet connection
- Stable therapeutic regimen for spasticity management (pharmacological and/or physiotherapy) for at least 6 months prior to enrollment
Exclusion Criteria:
- Presence of other neurological or systemic conditions causing additional motor impairment or musculoskeletal injury limiting movement
- Inability to perform performance outcomes even with assistive devices
- Planned or ongoing botulinum toxin injections or surgical interventions for spasticity reduction during the 12-week intervention period
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição cruzada
- Mascaramento: Dobro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Individualized Functional and Strength Exercise Intervention
Individualized functional and strength exercise intervention delivered via videoconference and supervised by a physiotherapist.
|
Individualized functional and strength exercise intervention delivered via videoconference and supervised by a physiotherapist.
Exercises are tailored according to Goal Attainment Scaling (GAS) and baseline physical activity level.
The program consists of two sessions per week and follows key training principles (individuality, overload, adaptation, specificity, continuity, reversibility, and variability) with progressive loading.
The intervention focuses on improving lower limb strength and functional mobility, particularly gait, and includes balance and gait training.
Sessions are scheduled with 2-3 day intervals.
Each exercise includes 1-3 sets of 8-15 repetitions, with 30-60 seconds rest between sets.
Training intensity ranges from 40-60% of maximal strength for sedentary participants and 50-70% for physically active participants.
|
|
Sem intervenção: No Intervention
No individualized prescription or real-time supervision will be provided during this phase.
They will receive printed educational materials containing general guidance on performing strength and functional exercises.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Spastic Paraplegia Rating Scale (SPRS)
Prazo: Baseline, 12 and 24 weeks
|
Clinician-reported outcome used to assess disease severity in hereditary spastic paraplegia (HSP).
It consists of 13 items evaluating gait, lower limb strength and spasticity, joint contractures, pain, and bladder and bowel function.
Total scores range from 0 to 52, with higher scores indicating greater disease severity.
|
Baseline, 12 and 24 weeks
|
|
Timed Up and Go Test (TUG) - maximum walking speed
Prazo: Baseline, 12 and 24 weeks
|
Performance outcome in which participants are instructed to stand up from a seated position, walk 3 meters, turn around, walk back, and sit down at maximum walking speed.
The time to complete the task is recorded.
|
Baseline, 12 and 24 weeks
|
|
Goal Attainment Scaling (GAS)
Prazo: Baseline, 12 and 24 weeks
|
individualized patient reported outcome measure used to assess the extent to which patient-specific goals are achieved during the intervention.
Each participant will define four main individualized goals at baseline.
Goals and expected levels of performance are defined individually for each participant and scored on a 5-point scale ranging from -2 to +2.
A score of 0 represents the expected level of achievement, positive scores (+1, +2) indicate better-than-expected outcomes, and negative scores (-1, -2) indicate less-than-expected outcomes.
|
Baseline, 12 and 24 weeks
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
10-Meter Walk Test (10MWT) - self-selected walking speed
Prazo: Baseline, 12 and 24 weeks
|
Performance outcome in which participants will walk at a comfortable, self-selected pace over a 10-meter distance.
A flying start will be used, allowing 2 meters for acceleration and 2 meters for deceleration outside the timed zone.
Walking speed (m/s) is calculated based on the time to complete the central 10-meter distance.
|
Baseline, 12 and 24 weeks
|
|
10-Meter Walk Test (10MWT) - maximum walking speed
Prazo: Baseline, 12 and 24 weeks
|
Performance outcome in which participants will walk at maximum walking speed over a 10-meter distance.
A flying start will be used, allowing 2 meters for acceleration and 2 meters for deceleration outside the timed zone.
Walking speed (m/s) is calculated based on the time to complete the central 10-meter distance.
|
Baseline, 12 and 24 weeks
|
|
Timed Up and Go (TUG) - self-selected walking speed
Prazo: Baseline, 12 and 24 weeks
|
Performance outcome in which participants are instructed to stand up from a seated position, walk 3 meters, turn around, walk back, and sit down at at a comfortable, self-selected pace .
The time to complete the task is recorded.
|
Baseline, 12 and 24 weeks
|
|
Falls Efficacy scale - International (Brazilian Portuguese)
Prazo: Baseline, 12 and 24 weeks
|
Patient-reported outcome used to assess concern about falling during daily activities in community-dwelling individuals.
It consists of 16 items covering functional and participation activities (e.g., sitting/standing from a chair, climbing stairs).
Each item is scored from 1 (not at all concerned) to 4 (very concerned), with total scores ranging from 16 to 64.
Higher scores indicate greater concern about falling.
|
Baseline, 12 and 24 weeks
|
|
36-Item Short Form Health Survey (SF-36) - Brazillian Portuguese
Prazo: Baseline, 12 and 24 weeks
|
Generic, patient-reported outcome of health-related quality of life.
It consists of 36 items covering multiple domains, including physical functioning, role limitations due to physical health, pain, general health, vitality, social functioning, role limitations due to emotional problems, and mental health.
Scores range from 0 to 100, with higher scores indicating better overall health status.
|
Baseline, 12 and 24 weeks
|
|
Medical Research Council (MRC) Muscle Strength Scale
Prazo: Baseline, 12 and 24 weeks
|
Clinician-reported outcome of muscle strength, graded from 0 (no contraction) to 5 (normal strength).
Lower limb muscle groups assessed include hip flexors and extensors, hip abductors and adductors, knee flexors and extensors, and ankle dorsiflexors and plantarflexors.
|
Baseline, 12 and 24 weeks
|
|
Modified Ashworth Scale (MAS)
Prazo: Baseline, 12 and 24 weeks
|
Clinician-reported outcome used to assess resistance to passive movement and muscle tone.
It is scored on a 5-point scale from 0 (normal muscle tone) to 4 (rigid in flexion or extension).
In this study, it will be applied to the hip adductor and knee flexor muscles to assess lower limb spasticity.
|
Baseline, 12 and 24 weeks
|
|
Patient Global Impression of Change (PGI-C)
Prazo: Baseline, 12 and 24 weeks
|
Patient-reported outcome measuring perceived overall improvement or worsening following the intervention.
It is a 7-point scale ranging from 1 (very much improved) to 7 (very much worse), capturing the patient's global assessment of change.
|
Baseline, 12 and 24 weeks
|
Outras medidas de resultado
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Handheld Dynamometry (microFET2)
Prazo: Baseline, 12 and 24 weeks
|
Digital health technology in which muscle strength will be assessed using a handheld dynamometer (microFET2) to measure peak force output in lower limb muscle groups including hip flexors and extensors, hip abductors and adductors, knee flexors and extensors, and ankle dorsiflexors and plantarflexors.
This provides an objective, quantitative measure of muscle strength (expressed in kgf) for comparison with clinical scales.
|
Baseline, 12 and 24 weeks
|
|
Instrumented Gait Analysis (Opal Sensors System) - Timed Up and Go test
Prazo: Baseline, 12 and 24 weeks
|
Digital health technology.
Biomechanical gait analysis will be performed using a six-sensor wearable system (Opal, Clario) to capture kinematic and spatiotemporal gait parameters.
Sit-to-stand, turning, and stand-to-sit times in seconds (1 decimal) will be recorded during and Timed Up and Go (TUG) test at both self-selected and maximum walking speeds.
|
Baseline, 12 and 24 weeks
|
|
Instrumented Gait Analysis (Opal Sensors System) - Cadence
Prazo: Baseline, 12 and 24 weeks
|
Digital health technology.
Biomechanical gait analysis will be performed using a six-sensor wearable system (Opal, Clario) to capture kinematic and spatiotemporal gait parameters.
Cadence in steps/min will be recorded during the 10-Meter Walk Test (10MWT).
Data will be collected at both self-selected and maximum walking speeds.
|
Baseline, 12 and 24 weeks
|
|
Instrumented Gait Analysis (Opal Sensors System) - Elevation Midswing, Lateral Step Variability, Circumduction
Prazo: Baseline, 12 and 24 weeks
|
Digital health technology.
Biomechanical gait analysis will be performed using a six-sensor wearable system (Opal, Clario) to capture kinematic and spatiotemporal gait parameters.
Elevation Midswing, Lateral Step Variability, Circumduction in cm will be recorded during the 10-Meter Walk Test (10MWT).
Data will be collected at both self-selected and maximum walking speeds.
|
Baseline, 12 and 24 weeks
|
|
Instrumented Gait Analysis (Opal Sensors System) - Gait Cycle Duration, Step Duration
Prazo: Baseline, 12 and 24 weeks
|
Digital health technology.
Biomechanical gait analysis will be performed using a six-sensor wearable system (Opal, Clario) to capture kinematic and spatiotemporal gait parameters.
Gait Cycle Duration and Step Duration in seconds will be recorded during the 10-Meter Walk Test (10MWT).
Data will be collected at both self-selected and maximum walking speeds.
|
Baseline, 12 and 24 weeks
|
|
Instrumented Gait Analysis (Opal Sensors System) - Gait Speed
Prazo: Baseline, 12 and 24 weeks
|
Digital health technology.
Biomechanical gait analysis will be performed using a six-sensor wearable system (Opal, Clario) to capture kinematic and spatiotemporal gait parameters.
Gait Speed in m/s will be recorded during the 10-Meter Walk Test (10MWT).
Data will be collected at both self-selected and maximum walking speeds.
|
Baseline, 12 and 24 weeks
|
|
Instrumented Gait Analysis (Opal Sensors System) - Stride Length
Prazo: Baseline, 12 and 24 weeks
|
Digital health technology.
Biomechanical gait analysis will be performed using a six-sensor wearable system (Opal, Clario) to capture kinematic and spatiotemporal gait parameters.
Stride Length in meters will be recorded during the 10-Meter Walk Test (10MWT).
Data will be collected at both self-selected and maximum walking speeds.
|
Baseline, 12 and 24 weeks
|
|
Instrumented Gait Analysis (Opal Sensors System) - Foot Strike Angle, Toe Off Angle, Toe Out Angle, Lumbar Coronal (RoM), Lumbar Sagittal (RoM), Lumbar Transverse (RoM), Trunk Coronal (RoM), Trunk Sagittal (RoM), Trunk Transverse (RoM)
Prazo: Baseline, 12 and 24 weeks
|
Digital health technology.
Biomechanical gait analysis will be performed using a six-sensor wearable system (Opal, Clario) to capture kinematic and spatiotemporal gait parameters.
Foot Strike Angle, Toe Off Angle, Toe Out Angle, Lumbar Coronal (RoM), Lumbar Sagittal (RoM), Lumbar Transverse (RoM), Trunk Coronal (RoM), Trunk Sagittal (RoM), Trunk Transverse (RoM) in ° degrees will be recorded during the 10-Meter Walk Test (10MWT).
Data will be collected at both self-selected and maximum walking speeds.
|
Baseline, 12 and 24 weeks
|
|
Instrumented Gait Analysis (Opal Sensors System) - Double Support, Single Limb Support, Stance, Swing, Terminal Double Support
Prazo: Baseline, 12 and 24 weeks
|
Digital health technology.
Biomechanical gait analysis will be performed using a six-sensor wearable system (Opal, Clario) to capture kinematic and spatiotemporal gait parameters.
Double Support, Single Limb Support, Stance, Swing, Terminal Double Support in Gait Cycle Time (%) will be recorded during the 10-Meter Walk Test (10MWT).
Data will be collected at both self-selected and maximum walking speeds.
|
Baseline, 12 and 24 weeks
|
Colaboradores e Investigadores
Patrocinador
Publicações e links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Doenças do Sistema Nervoso
- Doenças Neuromusculares
- Doenças Genéticas, Congênitas
- Doenças do Sistema Nervoso Periférico
- Doenças Neurodegenerativas
- Anomalias congénitas
- Distúrbios Heredodegenerativos, Sistema Nervoso
- Malformações do Sistema Nervoso
- Polineuropatias
- Neuropatia Sensorial e Motora Hereditária
- Doenças e Anormalidades Congênitas, Hereditárias e Neonatais
- Comportamento
- Paraplegia Espástica, Hereditária
- Atividade motora
Outros números de identificação do estudo
- 2023-0040
- CAAE: 67528023.6.0000.5327 (Outro identificador: CEP-HCPA)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .